Treatment of chronic myeloid leukemia in relapse after umbilical cord blood transplantation.

Abstract	Umbilical cord blood (UCB) is increasingly used as a source of hematopoietic progenitor cells for allotransplantation. Donor-derived buffy coat cells are considered optimal treatment for leukemia relapses after transplantation of allogeneic bone marrow. Experience with relapses after UCB transplants are sparse. Here we report a girl who received an UCB transplant for chronic myeloid leukemia, relapsed after three years, failed to respond to donor buffy coat cells, but achieved a complete hematologic, cytogenetic, and molecular remission on interferon-alpha.
Authors	V Bogdanić, I Aurer, B Labar, V Hitrec, D Nemet, M Mrsić
Journal	Haematologica (Haematologica) Vol. 83 Issue 6 Pg. 575-6 (Jun 1998) ISSN: 0390-6078 [Print] Italy
PMID	9676036 (Publication Type: Case Reports, Letter, Research Support, Non-U.S. Gov't)
Chemical References	Interferon-alpha
Topics	Child, Preschool Female Fetal Blood Hematopoietic Stem Cell Transplantation Humans Interferon-alpha (therapeutic use) Leukemia, Myeloid (pathology, therapy) Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!